Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Britain Courts Anthropic Amid US Defense Department Dispute 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2016 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet need, today announced that its president and chief executive officer, Ted W. Love, M.D. will participate in two upcoming investor conferences. Following are details for each presentation:
- Wells Fargo Securities Healthcare Conference
Date/Time: Wednesday, September 7, 2016 at 10:30 a.m. Eastern Time (ET)
Boston, MA
- Morgan Stanley Global Healthcare Conference
Date/Time: Wednesday, September 14, 2016 at 9:20 a.m. ET
New York, NY
The presentations will be webcast live and available for replay from GBT’s website at www.globalbloodtx.com in the Investors & Media section.
About Global Blood Therapeutics
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its lead product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD) and is currently evaluating GBT440 in a Phase 1/2 study in both healthy subjects and adults with SCD and a Phase 2a study in adolescents with SCD. GBT is also investigating GBT440 for the treatment of hypoxemic pulmonary disorders in an ongoing Phase 2a study in patients with idiopathic pulmonary fibrosis. In addition to GBT440, GBT is engaged in research and development activities with an oral kallikrein inhibitor for the prevention of hereditary angioedema attacks. To learn more, please visit: www.globalbloodtx.com.
Contact Information: Myesha Edwards (investors) Global Blood Therapeutics 650-351-4730 [email protected] Julie Normart (media) BrewLife 415-946-1087 [email protected]
